2002 at a glance

JANUARY


FEBRUARY


MARCH

Radiologist Elias Zerhouni nominated as NIH Director. TAG meetings at Office of AIDS Research (OAR), NIH. TAG co-sponsors 3rd International STI Workshop, Montreal.

APRIL

Meeting on Roche/Trimeris HIV fusion inhibitor, T-20, Chicago. TAG meets UNAIDS director Peter Piot, is critical of slow-moving UN system. *Indian PWA/activist Ashok Pillai dies of toxoplasmosis, a preventable disease. NYC artist/activist Frank Moore dies of aspergillosis.* Global Fund announces first awards to developing countries to prevent and treat AIDS, tuberculosis & malaria. TAG’s Mark Harrington meets with UNAIDS and World Health Organization (WHO) in Geneva.

MAY

JUNE


JULY

Activists disrupt U.S. Health & Human Services Secretary (HHS) Tommy Thompson’s speech at Barcelona AIDS conference to protest the Bush administration’s underfunding of domestic and global AIDS programs. First meeting of International Treatment Preparedness coalition. Memorial gathering for Linda Grinberg. ATAC/Community Constituency Group (CCG) training. TAG receives $87,750 for TB/HIV workshop.

AUGUST

Meeting on Roche’s Pegasys pegylated interferon for hepatitis C, Nutley, NJ. Washington Post covers administration “witch-hunt” against groups involved in July’s Thompson demo. Mark attends WHO scale-up meeting in Geneva. Richard Jefferys & Mark attend STI roundtable, Chicago.

SEPTEMBER


OCTOBER

TAG holds first TB/HIV Coinfection Education & Community Mobilization Workshop in Montreal before 33rd International Union Against Tuberculosis & Lung Diseases (IUATLD) conference. Eighteen activists from developing countries, attend. TAG meets USAID on treatment preparedness. AIDS leaders, including Mark Harrington, meet with Thompson at HHS and with White House AIDS staff.

NOVEMBER

Roche/Trimeris Fuzeon/T-20 meeting, NYC. HIV superinfection paper by Marcus Altfeld & Bruce Walker appears in Nature.

DECEMBER

TREATMENT ACTION GROUP, INC.
STATEMENTS OF FINANCIAL POSITION

ASSETS

Years ended December 31,

<table>
<thead>
<tr>
<th></th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$329,254</td>
<td>$222,869</td>
</tr>
<tr>
<td>Investment-donated marketable securities, at market</td>
<td>4,687</td>
<td>4,889</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>820</td>
<td>13,524</td>
</tr>
<tr>
<td>Unconditional promises to give – Unrestricted</td>
<td>52,074</td>
<td>47,240</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td><strong>386,835</strong></td>
<td><strong>288,522</strong></td>
</tr>
<tr>
<td>Property and equipment–net of accumulated depreciation</td>
<td>16,405</td>
<td>19,430</td>
</tr>
<tr>
<td>Security deposits</td>
<td>2,756</td>
<td>2,650</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$405,996</strong></td>
<td><strong>$310,602</strong></td>
</tr>
</tbody>
</table>

LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th></th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$17,343</td>
<td>$11,239</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>17,343</strong></td>
<td><strong>11,239</strong></td>
</tr>
<tr>
<td>Net assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>388,653</td>
<td>208,760</td>
</tr>
<tr>
<td>Restricted</td>
<td>(—)</td>
<td>90,603</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>388,653</strong></td>
<td><strong>299,363</strong></td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$405,996</strong></td>
<td><strong>$310,602</strong></td>
</tr>
</tbody>
</table>

STATEMENTS OF CASH FLOWS

Cash flows from operating activities:

Increase in net assets | $89,290       | $5,477
Adjustments to reconcile increase in net assets to net cash provided by operating activities:
Unrealized loss on marketable securities | 202           | 2,124
Realized (gain) loss on sale of marketable securities | (216)         | 132
Depreciation | 5,804         | 6,205
Donation of marketable securities | (2,816)       | (955)
(Increase) Decrease in current assets:
Prepaid expenses | 12,704        | (2,902)
Unconditional promises to give | (4,834)       | (16,685)
Security deposits | (106)         | (400)
(Decrease) Increase in current liabilities:
Accrued expenses | 6,104         | (9,788)

Net cash provided by (used in) operating activities | 106,132       | (16,792)

Cash flows from investing activities:
Proceeds from sale of marketable securities | 3,032         | 5,505
Purchases of property and equipment | (2,779)       | (13,943)

Net cash provided by (used in) investing activities | 253           | (8,438)

Net increase (decrease) in cash balance | 106,385       | (25,230)

Cash, beginning of year | 222,869       | 248,099

Cash, end of year | $329,254      | $222,869
### TREATMENT ACTION GROUP, INC.
#### STATEMENTS OF ACTIVITIES

**Years Ended December 31,**

<table>
<thead>
<tr>
<th></th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Changes in unrestricted net assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue and support:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bequests</td>
<td>$2,816</td>
<td>$955</td>
</tr>
<tr>
<td>Direct mail</td>
<td>32,514</td>
<td>47,674</td>
</tr>
<tr>
<td>Donations</td>
<td>7,728</td>
<td>40,762</td>
</tr>
<tr>
<td>Grants</td>
<td>565,805</td>
<td>447,539</td>
</tr>
<tr>
<td>Special event income</td>
<td>93,028</td>
<td>72,097</td>
</tr>
<tr>
<td>Travel and other reimbursement</td>
<td>3,457</td>
<td>6,314</td>
</tr>
<tr>
<td>Interest and dividend income</td>
<td>3,682</td>
<td>4,368</td>
</tr>
<tr>
<td><strong>Net assets released from donor restrictions</strong></td>
<td>709,030</td>
<td>619,709</td>
</tr>
<tr>
<td><strong>Total unrestricted revenue and support</strong></td>
<td>90,603</td>
<td>14,640</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antivirals Project</td>
<td>69,904</td>
<td>96,176</td>
</tr>
<tr>
<td>Federal Affairs/OAR Project</td>
<td>23,911</td>
<td>30,578</td>
</tr>
<tr>
<td>Basic Science Project</td>
<td>88,869</td>
<td>20,316</td>
</tr>
<tr>
<td>Infections and Oncology Project</td>
<td>52,731</td>
<td>70,250</td>
</tr>
<tr>
<td>Community Outreach</td>
<td>53,442</td>
<td>38,808</td>
</tr>
<tr>
<td>TAGline/Website</td>
<td>51,744</td>
<td>60,939</td>
</tr>
<tr>
<td>International Projects</td>
<td>115,281</td>
<td>113,477</td>
</tr>
<tr>
<td><strong>Supporting services expenses</strong></td>
<td>455,882</td>
<td>430,544</td>
</tr>
<tr>
<td>Management and general</td>
<td>100,288</td>
<td>120,051</td>
</tr>
<tr>
<td>Fundraising</td>
<td>63,584</td>
<td>61,381</td>
</tr>
<tr>
<td><strong>Total services expenses</strong></td>
<td>619,754</td>
<td>611,976</td>
</tr>
<tr>
<td><strong>Other income (expenses)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Realized gain (loss) on sale of marketable securities</td>
<td>216</td>
<td>(132)</td>
</tr>
<tr>
<td>Unrealized (loss) on marketable securities</td>
<td>(202)</td>
<td>(2,124)</td>
</tr>
<tr>
<td><strong>Total other income (expenses)</strong></td>
<td>14</td>
<td>(2,256)</td>
</tr>
<tr>
<td><strong>Increase in unrestricted net assets</strong></td>
<td>179,893</td>
<td>20,117</td>
</tr>
<tr>
<td><strong>Temporarily restricted net assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net assets released from restrictions:</td>
<td>(90,603)</td>
<td>(14,640)</td>
</tr>
<tr>
<td><strong>Decrease in temporary restricted net assets</strong></td>
<td>(90,603)</td>
<td>(14,640)</td>
</tr>
<tr>
<td><strong>Increase in total net assets</strong></td>
<td>89,290</td>
<td>5,477</td>
</tr>
<tr>
<td><strong>Net assets, beginning of year</strong></td>
<td>299,363</td>
<td>293,886</td>
</tr>
<tr>
<td><strong>Net assets, end of year</strong></td>
<td>$388,653</td>
<td>$299,363</td>
</tr>
</tbody>
</table>
MISSION STATEMENT

The Treatment Action Group (TAG) fights to find a cure for AIDS and to ensure that all people living with HIV receive the necessary treatment, care, and information they need to save their lives.

TAG focuses on the AIDS research effort, both public and private, the drug development process, and our nation’s and the world’s health care delivery systems.

We meet with researchers, pharmaceutical companies, and government officials, and resort when necessary to acts of civil disobedience, or to acts of Congress.

We strive to develop the scientific and political expertise needed to transform policy.

TAG is committed to working for and with all communities affected by HIV.

ACCOMPLISHMENTS

Over the past 12 years, TAG has:

- pushed Congress to strengthen AIDS research programs at the National Institutes of Health (NIH).
- helped move twenty new antiretroviral drugs onto the market.
- researched and provided accurate and up-to-date treatment information to hundreds of thousands of people with HIV and their providers, in the U.S. and around the world.
- successfully advocated with key Federal government decision-makers to more than double funding for AIDS research and treatment.
2002 CONTRIBUTORS

$100,000 or more
Royal S. Marks Foundation

$50,000 – $99,000
Newman’s Own, Inc
The Office of AIDS Research
Roche Pharmaceuticals

$25,000 – $49,999
Bristol-Myers Squibb Virology
GlaxoSmithKline Inc.
Merck & Co., Inc.

$10,000 – $24,999
Agouron Pharmaceuticals, Inc.
Boehringer-Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Squibb, Inc.
Pfizer, Inc.
JP Morgan Private Bank

$5,000 – $9,999
Abbott Laboratories
The Canary Charitable Foundation
Gilead Sciences, Inc.
The Gill Foundation
Robert J. McLain
The Michael Palm Foundation
Jerome C. Silvey/Starwood Capital Group Mgt, LLC
Richard M. Lynn & Joseph Evall
Mark O’Donnell

$2,500 – $4,999
Michael A. Becker
Paul L. Dietz
Jeffrey B. Soref
James O. Stepp & Peter Zimmer

$1,000 – $2,499
Michael Cunningham
Constance D’Aurizio
David Dechman
M. Lee Garrison
Steven & Judith Gluckstern
David Hollander
Lawrence H. Hoskins
Noel E.D. Kirnon
Mathilde Krim, Ph.D.
Cliff Love
Loring R. McAlpin/The Calamus Foundation
Mike McCune & Karen Kaye Smith-McCune
Michel Mercure
Adam Moss
Mary C. Rieth
Jeffrey S. Roth, M.D.
Bruce Schackman & Ed Sikov
Evan Schwartz & Robert Fitterman
William G. Spears
Nicholas L. Trivisonno
Tommy Tune
W. Kirk Wallace & Mark M. Sexton

$500 – $999
Katherine C. Ash
Susan Altman Miller
Benjamin & Christine Anagnos
John Beach
William Blumenthal
Robert A. Bronzo
Donn Campbell
John Campbell
Pam Donen
Sarah Donovan
Emer Featherstone
Michael Field
Linda Greenberg
James C. Hormel
Barbara F. Hughes
Michael D. Paley
Bette C. Slutsky
Michael & Melanie Wilson

$250 – $499
Peter Allen
David C. Bright, O.D.
Mark A. Callahan & Lisa Rowland Callahan
Scott P. Campbell
Tom Cody
Robert T. Crane
Alice Crary & Nathaniel Hupert
Edward J. Davis & Thomas Phillips
Edward DeBonis & Vincent Maniscalco
Peter Diffly
Carol DiPaolo
Benjamin F. Doller
Randall E. Fields
John S. Fitzgerald
Stephen K. Friedman

Michael E. Gluck, Ph.D.
Kenneth L. Goody
Thaddeus A. Grimes-Gruczka
Mark Harrington
Kenneth & Christina Hecht
Nancy E. Kass
Paul E. Kennedy
Horace S. Kenney, III
Alexandre A. Montagu, Esq.
Laura A. Morrison
Ana Oliveira
Jason I. Osher
Judith D. Peabody
William St. Clair Pugh
Gary Rose
Susan Rosen
James & Susan Shehan
Marvin Shulman
Betty C. Sikov
Jane Silver
Matthew J. Singer
Grant Stitt & Dr. Alan Shapiro
Robin S. Weiss & Allan H. Wimer
Guy T. Westmoreland
Gary Williams
David E. Winckoski
William J. Zwart

THANK YOU.